A nanobody 2C7 against human adenovirus and a preparation method and application thereof

By designing the nanobody 2C7 targeting human adenovirus type 55, the problem of the lack of specific nanobodies in the existing technology has been solved, realizing efficient diagnosis and treatment of human adenovirus and providing an effective diagnostic and treatment method.

CN117567601BActive Publication Date: 2026-06-26ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202311478618.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-08
Publication Date
2026-06-26
Estimated Expiration
2043-11-08

AI Technical Summary

Technical Problem

Currently, there is a lack of effective specific nanobodies for the diagnosis and treatment of human adenoviruses, especially for the highly pathogenic human adenovirus type 55. There are no effective prevention and treatment methods or vaccines available in the current technology.

Method used

A nanobody 2C7 targeting human adenovirus type 55 with specific binding ability was developed. By designing its complementary determinants CDR1, CDR2 and CDR3 and fusing them with the Fc fragment of immunoglobulin G, a nanobody fusion protein was constructed for the preparation of ELISA detection kits and therapeutic drugs.

Benefits of technology

It achieves high affinity binding and neutralizing activity against human adenovirus type 55, providing a means for early diagnosis and effective treatment, and supporting the prevention and control of human adenovirus infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004537404710000011
    Figure HDA0004537404710000011
  • Figure HDA0004537404710000012
    Figure HDA0004537404710000012
  • Figure HDA0004537404710000013
    Figure HDA0004537404710000013
Patent Text Reader

Abstract

The application discloses a nanobody 2C7 for human adenovirus and a preparation method and application thereof. The application belongs to the technical field of biotechnology and particularly relates to a nanobody 2C7 for human adenovirus and a preparation method and application thereof. The nanobody or antigen-binding fragment containing the nanobody for targeting human adenovirus has three complementarity determining regions CDR1, CDR2 and CDR3; the amino acid sequence of CDR1 is SEQ ID No. 1, the amino acid sequence of CDR2 is SEQ ID No. 2, and the amino acid sequence of CDR3 is SEQ ID No. 3. The nanobody 2C7 is fused with an Fc segment (hFc) of human immunoglobulin to obtain a fusion protein, and the obtained h2C7-hFc can effectively inhibit infection of human adenovirus type 55, and the IC 50 is 0.52 nM.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Humanized anti-human epidemic growth factor receptor (EGFR) antibody as well as encoding gene and application thereof

    CN102993305B

  • Anti-human IL-17 monoclonal antibody

    CN105315371B

  • Single-domain heavy-chain antibody aiming at adenovirus vector and application of single-domain heavy-chain antibody

    CN114605526A

  • Anti-adenovirus monoclonal antibody or antigen binding fragment thereof as well as nucleic acid molecule and application thereof

    CN116023474A